Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
Press release - 18/04/2024 Collagen: Researchers at the NMI decipher how it works in medical treatment Collagen has been used in ophthalmology since the 1990s, particularly in the treatment of corneal defects. However, why and how this technique works was only known in theory. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen led by Lu Fan have found the necessary evidence and can now reliably explain how this technique works.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collagen-researchers-nmi-decipher-how-it-works-medical-treatment
Microfluidics in medical technology - 24/03/2021 Ultra-compact: valves with shape memory actuators Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.https://www.gesundheitsindustrie-bw.de/en/article/news/ultra-compact-valves-shape-memory-actuators
Funding ACCELERATE Programme Funding programme, Funded by: Grünhof GmbH, sb_search.searchresult.label.programSubmissionDate: 12/02/2023 https://www.bio-pro.de/en/service/funding/accelerate-programm
Funding ACCELERATE Programme Funding programme, Funded by: Grünhof GmbH, sb_search.searchresult.label.programSubmissionDate: 12/02/2023 https://www.biooekonomie-bw.de/en/databases/funding/accelerate-programm
Press release - 23/09/2024 Carl Zeiss Foundation supports early career research group for biohybrid neuroimplants Dr Simon Binder has been awarded a five-year, 1.5 million euro grant from the Carl Zeiss Foundation for his research into novel neuroimplants. Binder will establish the early career research group ‘Biohybrid Neuroimplants based on Soft Hydrogel Electrodes’ at the University of Freiburg. It is affiliated with the research institutions BrainLinks-BrainTools.https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-foundation-supports-early-career-research-group-biohybrid-neuroimplants
Press release - 13/08/2024 Peptide Boronic Acids: New Prospects for Immunology A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy. https://www.gesundheitsindustrie-bw.de/en/article/press-release/peptide-boronic-acids-new-prospects-immunology
Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
Pipetting robot for academic research - 28/08/2024 goodBot GmbH: a third arm for researchers Repetitive tasks that researchers have to conduct in the lab tend to be tiring and often lead to errors. Precise pipetting is crucial for achieving reproducible results. Automation is underrepresented in research labs and existing pipetting robots are unsuitable for scientists. This is why Dr. Julius Wiener, Tobias Zundel and Oliver Brunner decided to found the company goodBot GmbH and develop a pipetting robot tailored to academic research.https://www.gesundheitsindustrie-bw.de/en/article/news/goodbot-gmbh-third-arm-researchers
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
Zero Bullshit Company - 31/05/2021 From being thrown away to becoming a recycled product - Stuttgart start-up produces healthy snacks Throwing away food? The Stuttgart-based start-up Zero Bullshit Company is declaring war on food wastage by making nutrient-rich products largely from food industry leftovers. The three food technologists who created this transparent brand are looking to develop more than just delicious and nutritious products.https://www.biooekonomie-bw.de/en/articles/news/being-thrown-away-becoming-recycled-product-stuttgart-start-produces-healthy-snacks
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Dossier - 22/10/2012 Environmental biotechnology Biotechnologists are increasingly learning how to apply the knowledge about biological metabolic processes in the field of environmental protection including waste management and environmental rehabilitation. Environmental biotechnology is a field with great potential. In future bacteria and other microorganisms will most likely also contribute to sustainability and cost efficiency in other areas including the cosmetics and detergent industry as…https://www.biooekonomie-bw.de/en/articles/dossiers/environmental-biotechnology
Development of biogenic packaging - 16/11/2020 Sustainable packaging - the devil is in the detail Modern packaging often boils down to a tick list of biogenic origin and/or biodegradability. But comprehensive sustainable packaging concepts need more than just that. Perishable foods, for example, require special barrier properties. The Albstadt-Sigmaringen University of Applied Sciences is researching packaging concepts for their sustainability.https://www.biooekonomie-bw.de/en/articles/news/sustainable-packaging-devil-detail
Press release - 18/03/2021 DBFZ presents exensively expanded online database on biogenic raw materials Systematically prepared and easily accessible research data can provide an essential basis for decision-making for a wide range of stakeholders from politics, science and industry. The resource database developed by the DBFZ, which contains a wealth of information on various biomass potentials and their current use, has been extensively expanded and is now also available in two languages (DE/EN) with a variety of new functionalities.https://www.biooekonomie-bw.de/en/articles/pm/dbfz-presents-exensively-expanded-online-database-biogenic-raw-materials
Press release - 23/03/2021 AFYREN and Südzucker reach long term deal to supply factory producing biobased organic acids AFYREN secures procurement of sugar beet co-products, major feedstock for industrial- scale production of its sustainable chemicals.https://www.biooekonomie-bw.de/en/articles/pm/afyren-and-sudzucker-reach-long-term-deal-supply-factory-producing-biobased-organic-acids
Press release - 03/05/2021 Bioactive paper coatings to replace plastic for packaging foods The amount of plastic waste increases every year. Some of this waste is due to plastic packaging used to protect food. As part of the “BioActiveMaterials” project, researchers at the Fraunhofer-Gesellschaft have developed an eco-friendly coating for paper packaging. With this, not only is plastic saved, but the coating of plant-based proteins and waxes also extends the shelf life of the food.https://www.biooekonomie-bw.de/en/articles/pm/bioactive-paper-coatings-replace-plastic-packaging-foods
Press release - 09/12/2021 New research project in mathematical oncology A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Press release - 21/09/2022 ERC funding: How to deliver gene therapies to a specific target site? With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
Press release - 27/05/2021 Coffee´s pulp waste becomes organic compost The pulp of coffee beans is considered a waste product on coffee plantations, which is usually thrown away or dumped into rivers - with significant negative consequences for climate change and the environment. Macarena San Martín-Ruiz from the University of Stuttgart is working with Coopetarrazú, the largest coffee cooperative in Costa Rica, to find out how the mixture of pulp and husks can be turned into organic compost and thus protect the…https://www.biooekonomie-bw.de/en/articles/pm/coffee-s-pulp-waste-becomes-organic-compost
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
Press release - 14/09/2023 The Cultivated B Initiated Pre-Submission Process towards EFSA Certification for Cultivated Sausage The Cultivated B (TCB) began discussions with the European Food Safety Authority (EFSA) and officially entered the pre-submission process for novel food approval of a novel or non-farmed sausage product. Subsequent to the official submission, TCB will emerge as world’s first biotech company to apply for EFSA certification for cultivated meat. This is a pivotal first step in the evolution of the cultivated meat market.https://www.biooekonomie-bw.de/en/articles/pm/cultivated-b-initiated-pre-submission-process-towards-efsa-certification-cultivated-sausage
Press release - 13/01/2022 Turning harmful CO2 into useful chemicals Making important raw materials for fine chemicals out of carbon dioxide really works. As part of the Max Planck collaborative project eBioCO2n, a team of researchers from Fraunhofer IGB have successfully performed a first ever fixation of CO2 via a multi-enzyme enzyme reaction driven by electricity yielding a prospective intermediate for the chemical industry. The process for electro-biocatalytic CO2 fixation was recently published and is…https://www.biooekonomie-bw.de/en/articles/pm/turning-harmful-co2-useful-chemicals
NMI project WOUNDSENS - 23/10/2024 Wound monitoring using sensory nanofibres Monitoring the condition of chronic, non-healing wounds requires wound dressings to be changed at short, regular intervals. In the EU-funded WOUNDSENS project, researchers at the NMI in Reutlingen are using electrospinning to produce novel types of wound dressings. These consist of biosensory fibres that send information about the condition of the wound to the outside, thereby improving inflammation detection.https://www.gesundheitsindustrie-bw.de/en/article/news/wound-monitoring-using-sensory-nanofibres
Press release - 06/07/2021 High-throughput metabolic profiling of single cells Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-throughput-metabolic-profiling-single-cells
Press release - 24/11/2022 Green chemistry: BAM investigates pharmaceutical production without solvents and CO2 emissions The Bundesanstalt für Materialforschung und -prüfung (BAM) is developing a more sustainable process to produce active pharmaceutical ingredients in a major EU project: The pilot project is intended to demonstrate the advantages of mechanochemistry for more environmentally friendly and CO2-neutral pharmaceutical production.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gruene-chemie-bam-erforscht-arzneimittelproduktion-ohne-loesungsmittel-und-co2-ausstoss
Biotech in outer space - 06/07/2022 yuri, a space start-up: weightlessness for commercial research Growing cells without the effect of gravity could revolutionise drug development. A start-up called yuri on Lake Constance enables made-to-measure experiments on the ISS for stem cells, artificial organs, surfaces and materials. On board the next mission are some mini-cell labs from Berlin's Charité and Goethe University Frankfurt.https://www.gesundheitsindustrie-bw.de/en/article/news/yuri-space-start-weightlessness-commercial-research
Press release - 18/07/2023 National Research Center for cutting-edge AI research in Tübingen celebrates inception On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nationales-forschungszentrum-fuer-ki-spitzenforschung-tuebingen-feiert-seine-gruendung
Press release - 01/03/2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 31/01/2023 ERC Consolidator Grants for Two Researchers from KIT In the 2022 allocation round for the award of the prestigious Consolidator Grants of the European Research Council, researchers of Karlsruhe Institute of Technology (KIT) have been successful. For their projects in the fields of photovoltaics and medical sensor technology, physicist Ulrich W. Paetzold and chemist Frank Biedermann will receive approximately two million euros over the next five years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-fuer-zwei-forscher-des-kit
Press release - 26/04/2023 Simply EGG-genious: Students invent edible packaging from eggshells Ready-made meals are ideal for quickly satisfying hunger. However, the quick snacks produce a lot of environmentally harmful plastic waste. To tackle this problem, the student team EDGGY from the University of Hohenheim in Stuttgart rolled up its sleeves and developed edible packaging made from eggshells and other plant-based raw materials. And even better: they simply dissolve in the hot water and can be eaten as an additional protein boost. https://www.biooekonomie-bw.de/en/articles/pm/Simply-EGG-genious-Students-invent-edible-packaging-from-eggshells
Dossier - 10/11/2014 Cell and gene therapies from bench to bedside While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Press release - 25/09/2024 How developmental signals can contribute to Genomic Mosaicism Certain developmental signals play a significant role in maintaining our genetic blueprints. They prevent alterations in the genome, known as mosaicism. The underlying biological mechanism helps the DNA to produce an identical copy of itself during cell division using the original genetic blueprint. However, it can also contribute to genomic mosaicism during nerve cell development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-developmental-signals-can-contribute-genomic-mosaicism
The Baden-Württemberg healthcare industry The pharmaceutical industry https://www.gesundheitsindustrie-bw.de/en/location/pharma
Press release - 17/06/2024 DNA as building material for tiny machines and artificial cells Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dna-building-material-tiny-machines-and-artificial-cells
Dossier - 30/09/2014 Industrial biotechnology a challenging change to the raw material base Biogenic raw materials have never been as popular as they are now. Efforts to tap renewable carbon resources are already underway, despite the fact that new oil drilling technologies are boosting fossil fuel stockpiles. In the medium term, industry will have to expand its raw materials base, and in the long term it may have to renew it completely. Industrial biotechnology is one of the key technologies in the transition.https://www.biooekonomie-bw.de/en/articles/dossiers/industrial-biotechnology-a-challenging-change-to-the-raw-material-base
Press release - 24/05/2024 Research Training Group on Cancer Surgery: German Research Foundation approves second funding period Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-training-group-cancer-surgery-german-research-foundation-approves-second-funding-period
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Press release - 26/10/2022 Around EUR 5 million for research on the energy transformation What will the energy systems of the future look like? What technical foundations do we need, and how can the upcoming transformation be shaped in such a way that we involve all actors in society? Answers to such questions are to be provided by four research projects funded by the Carl Zeiss Foundation (CZS) as part of the “CZS Breakthroughs – Energy Systems of the Future” program. One of these is based at the University of Stuttgart.https://www.bio-pro.de/en/activities/biological-transformation/aktuelles/rund-5-millionen-euro-fuer-transformationsforschung-zur-energiewende
Press release - 08/12/2022 Leibniz-Prize for Prof. Achim Menges The German Research Foundation (DFG) has awarded the 2023 Gottfried Wilhelm Leibniz Prize to Prof. Achim Menges, head of the Institute for Computational Design and Construction at the University of Stuttgart. The award, which is endowed with EUR 2.5 million, is considered by many the most important research prize in Germany.https://www.bio-pro.de/en/activities/biological-transformation/aktuelles/leibniz-preis-fuer-prof-achim-menges
Press release - 08/12/2022 Leibniz-Prize for Prof. Achim Menges The German Research Foundation (DFG) has awarded the 2023 Gottfried Wilhelm Leibniz Prize to Prof. Achim Menges, head of the Institute for Computational Design and Construction at the University of Stuttgart. The award, which is endowed with EUR 2.5 million, is considered by many the most important research prize in Germany.https://www.biooekonomie-bw.de/en/articles/pm/leibniz-preis-fuer-prof-achim-menges
Press release - 27/07/2023 Materials Research: Biocatalytic Foams of Tremendous Stability and Activity Industrial biocatalysis with enzymes is deemed to be a “game changer” in the development of a sustainable chemical industry. Enzymes can be used to synthesize an impressive range of complex molecules. Researchers of KIT have now developed a new class of materials by producing enzyme foams of tremendous stability and activity. The researchers have already filed a patent application on the process to produce enzyme foams.https://www.biooekonomie-bw.de/en/articles/pm/materials-research-biocatalytic-foams-tremendous-stability-and-activity
Press release - 07/02/2025 Multiple myeloma: When cancer cells break out of the bone marrow, a dangerous diversity arises A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response. https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-myeloma-when-cancer-cells-break-out-bone-marrow-dangerous-diversity-arises
Press release - 24/06/2024 Digital babies created to improve infant healthcare Researchers at University of Galway, the Heidelberg Institute for Theoretical Studies (HITS) Heidelberg University, and Heidelberg University Hospital have created digital babies to better understand infants’ health in their critical first 180 days of life. The international team created computer models that simulate the unique metabolic processes of each baby. The models can help to better understand rare metabolic diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-babies-created-improve-infant-healthcare
Press release - 05/07/2024 The Symphony of Organelles With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules. https://www.gesundheitsindustrie-bw.de/en/article/press-release/symphony-organelles
Dossier - 20/12/2012 Medical technology serving healthcare Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.https://www.gesundheitsindustrie-bw.de/en/article/dossier/medical-technology-serving-healthcare
Press release - 12/04/2022 Technology transfer award for PCR rapid test device for infection diagnostics Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
Press release - 20/05/2022 RoofKIT: How to Build in a Recycling-Oriented and Sustainable Way The construction industry consumes large amounts of energy resources and produces tons of waste. At the Solar Decathlon Europe 21/22 university competition, students and researchers from KIT are eager to demonstrate that the building sector is already compatible with a functioning circular economy. The task of the interdisciplinary “RoofKIT” team is to convert previously unused roofs of buildings into usable spaces.https://www.biooekonomie-bw.de/en/articles/pm/roofkit-how-build-recycling-oriented-and-sustainable-way
Press release - 25/07/2023 Green Genetic Engineering: Making Mendel’s Dream Come True with Molecular Scissors Molecular biologist Professor Holger Puchta from KIT is granted funding within a Reinhart Koselleck Project by the German Research Foundation (DFG) for work on specific restructuring of plant genomes. Puchta, a pioneer of green genetic engineering, has used molecular scissors in plants for 30 years now. His new project is aimed at using the CRISPR/Cas method to freely combine genes in crops, thus making Gregor Mendel’s dream come true.https://www.biooekonomie-bw.de/en/articles/pm/green-genetic-engineering-making-mendels-dream-come-true-molecular-scissors
Dossier - 13/05/2013 The human proteome the next major goal The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 01/03/2023 Pseudomonas aeruginosa Bacteria produce a molecule that paralyzes immune system cells Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pseudomonas-aeruginosa-bakterien-stellen-ein-molekuel-her-das-zellen-des-immunsystems-laehmt
Press release - 16/01/2023 GoDanuBio’s contribution to the bioeconomisation of the Danube Region GoDanuBio supported the set-up of policy frameworks and participative governance schemes in the participating regions. The main topics were circular bioeconomy, sustainable rural development and rural-urban interactions.https://www.bio-pro.de/en/information/press-release/aufbruch-zu-mehr-biooekonomie-im-donauraum
Dossier - 09/12/2013 Industrial biotechnology biological resources for industrial processes Industrial or white biotechnology uses microorganisms and enzymes to produce goods for industry, including chemicals, plastics, food, agricultural and pharmaceutical products and energy carriers. Renewable raw materials and increasingly also waste from agriculture and forestry are used for the manufacture of industrial goods.https://www.biooekonomie-bw.de/en/articles/dossiers/industrial-biotechnology-biological-resources-for-industrial-processes
Press release - 20/01/2025 New approach to fighting cancer: energy trap for tumor cells Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming process. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-fighting-cancer-energy-trap-tumor-cells
Press release - 05/03/2024 New Center for Synthetic Genomics Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
Press release - 07/06/2024 German Research Foundation honors researchers for animal testing alternatives Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-research-foundation-honors-researchers-animal-testing-alternatives
Article - 28/03/2019 Supporting the human use of artificial intelligence Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible. https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
Press release - 21/10/2022 Carl-Zeiss-Stiftung supports research project on wood-based materials at the University of Freiburg The Carl Zeiss Foundation is funding the "DELIVER - Data-driven Engineering of Sustainable Living Materials" project at the University of Freiburg in its "CZS Wildcard" program. In the project, scientists from the Freiburg Clusters of Excellence CIBSS and livMatS will develop sustainable wood-based materials whose properties can be precisely controlled.https://www.bio-pro.de/en/activities/biological-transformation/aktuelles/carl-zeiss-stiftung-supports-research-project-wood-based-materials-university-freiburg
Press release - 29/01/2021 The added value of compostable plastics for the circular economy For quite some time now, the European Commission (EC) is putting a special focus on biodegradable and compostable polymers when assessing the general role of bioplastics. https://www.biooekonomie-bw.de/en/articles/pm/added-value-compostable-plastics-circular-economy
Press release - 21/10/2022 Carl-Zeiss-Stiftung supports research project on wood-based materials at the University of Freiburg The Carl Zeiss Foundation is funding the "DELIVER - Data-driven Engineering of Sustainable Living Materials" project at the University of Freiburg in its "CZS Wildcard" program. In the project, scientists from the Freiburg Clusters of Excellence CIBSS and livMatS will develop sustainable wood-based materials whose properties can be precisely controlled.https://www.biooekonomie-bw.de/en/articles/pm/carl-zeiss-stiftung-foerdert-forschungsvorhaben-der-universitaet-freiburg-zu-holzbasierten-werkstoffen
Press release - 13/01/2025 New tool for synthetic biology Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic loads into cells. This opens up a new way for the targeted administration of medication and other therapeutic interventions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-tool-synthetic-biology
Press release - 11/01/2023 Newly discovered surface structures may affect immune function Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
Our services & offers for company founders EXI Start-Up Voucher https://www.bio-pro.de/en/projects/general-projects/exi
Press release - 25/05/2021 How “paralyzed” immune cells can be reactivated against brain tumors Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
Press release - 20/10/2022 Cytoskeleton acts as cells’ bouncer for bacteria Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
Press release - 12/01/2023 “Zone of uncertainty” in the brain influences its ability to form new memories Researchers at the University of Freiburg Medical School led by Prof. Dr. Johannes Letzkus and the Max Planck Institute for Brain Research have discovered that a little-studied area of the brain, the "zone of uncertainty" or "zona incerta," communicates with the neocortex in unconventional ways to rapidly control memory formation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zone-der-ungewissheit-im-gehirn-beeinflusst-bildung-von-erinnerungen
Press release - 08/03/2023 Green gold: Torrefied biomass to replace coal and oil In February, the Estonian-based startup New Standard Oil successfully commissioned their first industrial-scale prototype for drying and torrefaction of biogenic feedstock operating with superheated steam at atmospheric pressure.https://www.biooekonomie-bw.de/en/articles/pm/green-gold-torrefied-biomass-replace-coal-and-oil
Vaccine development - 25/05/2021 Vaccines - a beacon of hope in the fight against pandemics Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
Press release - 14/03/2024 Next milestone in the treatment of liver tumors and acute and chronic liver diseases The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
Press release - 10/06/2021 Nose2Brain – Active substances without detour through the nose into the brain Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…https://www.gesundheitsindustrie-bw.de/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 19/10/2022 Molecular structure of one of the most important receptors in the immune system unraveled Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled